1. |
- Daly, AK, et al.
(author)
-
Nomenclature for human CYP2D6 alleles
- 1996
-
In: Pharmacogenetics. - : Ovid Technologies (Wolters Kluwer Health). - 0960-314X. ; 6:3, s. 193-201
-
Journal article (peer-reviewed)
|
|
2. |
|
|
3. |
- Eichelbaum, M, et al.
(author)
-
Pharmacogenomics and individualized drug therapy
- 2006
-
In: Annual review of medicine. - : Annual Reviews. - 0066-4219 .- 1545-326X. ; 57, s. 119-137
-
Journal article (peer-reviewed)abstract
- Pharmacogenetics deals with inherited differences in the response to drugs. The best-recognized examples are genetic polymorphisms of drug-metabolizing enzymes, which affect about 30% of all drugs. Loss of function of thiopurine S-methyltransferase (TPMT) results in severe and life-threatening hematopoietic toxicity if patients receive standard doses of mercaptopurine and azathioprine. Gene duplication of cytochrome P4502D6 (CYP2D6), which metabolizes many antidepressants, has been identified as a mechanism of poor response in the treatment of depression. There is also a growing list of genetic polymorphisms in drug targets that have been shown to influence drug response. A major limitation that has heretofore moderated the use of pharmacogenetic testing in the clinical setting is the lack of prospective clinical trials demonstrating that such testing can improve the benefit/risk ratio of drug therapy.
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
|
|
9. |
|
|
10. |
|
|